France's 2026 Economic Growth and Pharmacy Sector Financial Outlook Reveal Moderate Gains and Challenges

Economic forecasts for 2026 indicate a cautiously optimistic outlook for France and its key sectors. According to BNP Paribas Economic Research, France's GDP growth is projected at 1.1% for 2026, following an estimated 0.8% growth in 2025. This improvement is linked closely to a rebound in German economic activity and is part of the broader Eurozone growth estimate of 1.6%, despite ongoing geopolitical and trade tensions.

Within the pharmaceutical retail sector, the 2025 financial performance of French pharmacies, as reported by the FSPF, shows a 2.17% increase in overall remuneration compared to previous years. This increase aligns with earlier forecasts and stems largely from a significant 21% rise in prescription fees alongside a nearly 6% growth in regulated margins. However, the pharmacy network faced a setback due to the discontinuation of COVID-19 test reimbursement, leading to a loss exceeding €70 million. This loss was partially offset by a €46 million boost from vaccination fees and additional income from chronic patient management.

Despite these positive financial results, structural challenges remain. The slow rollout of support measures for pharmacies in fragile areas and economic pressures linked to generic drug pricing negotiations paint a mixed picture for sustainability. The 2026 social security financing law (LFSS) introduces price reductions, which suggest that increases in remuneration will likely not exceed 2%. Consequently, the FSPF emphasizes the need for negotiations with the Health Insurance system to secure economic stability for pharmacies through 2030. They advocate for significant state investments to prevent any pharmacy from being economically marginalized.

This economic and sectoral snapshot underlines France’s moderate yet steady growth amidst a complex global environment. The pharmaceutical sector, a critical part of France’s healthcare infrastructure, is balancing gains with emerging cost pressures, highlighting the importance of policy support in preserving its viability.

"For the benefit of the population, the state must invest heavily in the pharmacy network to ensure the sustainability of pharmacy businesses," the FSPF stated, emphasizing vigilance to ensure equitable support for all pharmacies.